Clinical aspects of inflammation in Alzheimer's disease

References

• Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000; 54: 588–593
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen versus placebo on Alzheimer's disease progression: A randomized controlled trial. Journal of the American Medical Association 2003; 289: 2819–2826
   PubMed Web of Science ®Google Scholar
• Apelt J, Schliebs R. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Research 2001; 894: 21–30
   PubMed Web of Science ®Google Scholar
• Banaszak-Holl J, Fendrick AM, Foster NL, Herzog AR, Kabeto MU, Kent DM, et al. Predicting nursing home admission: Estimates from a 7-year follow-up of a nationally representative sample of older Americans. Alzheimer's disease & Associated Disorders 2004; 18: 83–89
   PubMed Web of Science ®Google Scholar
• Banati RB. Visualising microglial activation in vivo. Glia 2002; 40: 206–217
   PubMed Web of Science ®Google Scholar
• Banati RB. Neuropathological imaging: In vivo detection of glial activation as a measure of disease and adaptive change in the brain. British Medical Bulletin 2003; 65: 121–131
   PubMed Web of Science ®Google Scholar
• Bellinger FP, Madamba SG, Siggins GR. Interleukin-1 inhibits synaptic strength and long-term potentiation in the CA3 region of mouse hippocampal slices. European Journal of Pharmacology 1993; 181: 323–326
   Google Scholar
• Bellinger FP, Madamba SG, Campbell IL, Siggins GR. Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral over-expression of interleukin-6. Neuroscience Letters 1995; 198: 95–98
   PubMed Web of Science ®Google Scholar
• Beglopoulos V, Sun X, Saura CA, Lemere CA, Kim RD, Shen J. Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. Journal of Biological Chemistry 2004; 279: 46907–46914
   PubMed Web of Science ®Google Scholar
• Benveniste EN, Nguyen VT, O’Keefe GM. Immunological aspects of microglia: Relevance to Alzheimer's disease. Neurochemistry International 2001; 39: 381–391
   PubMed Web of Science ®Google Scholar
• Bharucha AJ, Pandav R, Shen C, Dodge HH, Ganguli M. Predictors of nursing facility admission: A 12-year epidemiological study in the United States. Journal of the American Geriatric Society 2004; 52: 434–439
   PubMed Web of Science ®Google Scholar
• Binetti G, Magni E, Padovani A, Cappa SF, Bianchetti A, Trabucchi M. Executive dysfunction in early Alzheimer's disease. Journal of Neurology, Neurosurgery & Psychiatry 1996; 60: 91–93
   PubMed Web of Science ®Google Scholar
• Birks J, Grimley Evans J, Iakovidou, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database System Reviews 2000; 4: CD001191
   PubMedGoogle Scholar
• Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S. Galantamine provides sustained benefits in patients with ‘advanced moderate’ Alzheimer's disease for at least 12 months. Dementia & Geriatric Cognitive Disorders 2003; 15(2)79–87
   PubMed Web of Science ®Google Scholar
• Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold HH, Walker L. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. Journal of Neuroscience 2002; 22: 515–522
   PubMed Web of Science ®Google Scholar
• Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, et al. Patterns of brain activation in people at risk for Alzheimer's disease. New England Journal of Medicine 2000; 343: 450–456
   PubMed Web of Science ®Google Scholar
• Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, Steffens DC, Norton MC, et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: The Cache County Study. Neurology 1999; 53: 321–331
   PubMed Web of Science ®Google Scholar
• Breitner JC. NSAIDs and Alzheimer's disease: How far to generalize from trials?. Lancet Neurology 2003; 2: 527
   PubMed Web of Science ®Google Scholar
• Cabranes JA, De Juan R, Encinas M, Marcos A, Gil P, Fernandez C, et al. Relevance of functional neuroimaging in the progression of mild cognitive impairment. Neurological Research 2004; 26: 496–501
   PubMed Web of Science ®Google Scholar
• Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In vivo measurement of activated microglia in dementia. Lancet 2001; 358: 461–467
   PubMed Web of Science ®Google Scholar
• Capuron L, Miller AH. Cytokines and psychopathology: Lessons from interferon-alpha. Biological Psychiatry 2004; 56: 819–824
   PubMed Web of Science ®Google Scholar
• Chao CC, Hu S, Ehrlich L, Peterson PK. Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: Involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain, Behaviour & Immunity 1995; 9: 355–365
   PubMed Web of Science ®Google Scholar
• Chen P, Ganguli M, Mulsant BH, Dekosky ST. The temporal relationship between depressive symptoms and dementia: a community based prospective study. Archives of General Psychiatry 1999 2003; 56: 261–266
   Web of Science ®Google Scholar
• Collie A, Maruff P. The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment. Neuroscience & Biobehavioural Reviews 2000; 24: 365–374
   PubMed Web of Science ®Google Scholar
• Cotter RL, Burke WJ, Thomas VS, Potter JF, Zheng J, Gendelman HE. Insights into the neurodegenerative process of Alzheimer's disease: A role for mononuclear phagocyte-associated inflammation and neurotoxicity. Journal of Leukocyte Biology 1999; 65: 416–427
   PubMed Web of Science ®Google Scholar
• Craft JM, Watterson DM, Frautschy SA, Van Eldik LJ. Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo. Neurobiology & Aging 2004a; 25: 1283–1292
   PubMed Web of Science ®Google Scholar
• Craft JM, Van Eldik LJ, Zasadzki M, Hu W, Watterson DM. Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation. Journal of Molecular Neuroscience 2004b; 24(1)115–122
   PubMed Web of Science ®Google Scholar
• De Luigi A, Pizzimenti S, Quadri P, Lucca U, Tettamanti M, Fragiacomo C, et al. Peripheral inflammatory response in Alzheimer's disease and multi-infarct dementia. Neurobiology of Disease 2002; 11: 308–314
   PubMed Web of Science ®Google Scholar
• DeBruyne JC, Versijpt J, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. European Journal of Neurology 2003; 10: 257–264
   PubMed Web of Science ®Google Scholar
• Devanand DP, Sano M, Tang MX, Taylor S, Gurland BJ, Wilder D, et al. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Archives of General Psychiatry 1996; 53: 175–182
   PubMed Web of Science ®Google Scholar
• Engelborghs S, De Brabander M, De Cree J, D'Hooge R, Geerts H, Verhaegen H, et al. Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochemistry International 1999; 34: 523–530
   PubMed Web of Science ®Google Scholar
• Engelhart MJ, Geerlings MI, Meijer J, Kiliaan R, Ruitenberg A, van Swieten JC, et al. Inflammatory proteins in plasma and the risk of dementia: The Rotterdam study. Archives in Neurology 2004; 61: 668–672
   PubMed Web of Science ®Google Scholar
• Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, et al. Neurogenesis in the adult human hippocampus. Nature Medicine 1998; 4(11)1313–1317
   PubMed Web of Science ®Google Scholar
• Gambi F, Reale M, Iarlori C, Salone A, Toma L, Paladini C, et al. Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells. Journal of Clinical Psychopharmacology 2004; 24: 314–321
   PubMed Web of Science ®Google Scholar
• Garlind A, Brauner A, Hojeberg B, Basun H, Schultzberg M. Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. Brain Research 1999; 826: 112–116
   PubMed Web of Science ®Google Scholar
• Gasparini L, Ongini E, Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: Old and new mechanisms of action. Journal of Neurochemistry 2004; 91: 521–536
   PubMed Web of Science ®Google Scholar
• Gasparini L, Ongini E, Wilcock D, Morgan D. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Research Reviews 2005; 48: 400–408
   PubMed Web of Science ®Google Scholar
• Geerlings MI, Schoeveers RA, Beekman ATF, Jonker C, Deeg DJ, Schmand B, et al. Depression and risk of cognitive decline and Alzheimer's disease. British Journal of Psychiatry 2000; 176: 568–575
   PubMed Web of Science ®Google Scholar
• Gerhard A, Watts J, Trender-Gerhard I, Turkheimer F, Banati RB, Bhatia K, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Movement Disorders 2004; 19: 1221–1226
   PubMed Web of Science ®Google Scholar
• Gerhard A, Schwarz J, Myers R, Wise R, Banati RB. Evolution of microglial activation in patients after ischemic stroke: A [11C](R)-PK11195 PET study. Neuroimage 2005; 15(24)591–595
   Web of Science ®Google Scholar
• Giulian D, Haverkamp LJ, Yu JH, Karshin W, Tom D, Li J, et al. Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. Journal of Neuroscience 1996; 16: 6021–6037
   PubMed Web of Science ®Google Scholar
• Gotz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, et al. Transgenic animal models of Alzheimer's disease and related disorders: Histopathology, behavior and therapy. Molecular Psychiatry 2004; 9: 664–683
   PubMed Web of Science ®Google Scholar
• Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, et al. Glial-neuronal interactions in Alzheimer's disease: The potential role of a ‘cytokine cycle’ in disease progression. Brain Pathology 1998; 8: 65–72
   PubMed Web of Science ®Google Scholar
• Grimaldi LME, Casadei VM, Ferri C, Veglia F, Licastro F, Annoni G, et al. Association of early onset Alzheimer's disease with an Interleukin-1a gene polymorphism. Annals of Neurology 2000; 47: 361–365
   PubMed Web of Science ®Google Scholar
• Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Archives in Neurology 2003; 60: 729–736
   PubMed Web of Science ®Google Scholar
• Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP. Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. Journal of Neurochemistry 2002; 83: 1509–1524
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Archives in Neurology 2003; 60: 1119–1122
   PubMed Web of Science ®Google Scholar
• Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. PNAS 1997; 94: 1500–1505
   PubMed Web of Science ®Google Scholar
• Huberman M, Sredni B, Stern L, Kott E, Shalit F. IL-2 and IL-6 secretion in dementia: Correlation with type and severity of disease. Journal of Neurological Science 1995; 130: 161–164
   PubMed Web of Science ®Google Scholar
• in't Veld BA, Launer LJ, Hoes AW, Ott A, Hofman A, Breteler MM, et al. NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiology & Aging 1998; 19: 607–611
   PubMed Web of Science ®Google Scholar
• Jack CR, Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003; 60: 253–260
   PubMed Web of Science ®Google Scholar
• Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, et al. Increased hippocampal neurogenesis in Alzheimer's disease. Proceedings of the National Academy of Science USA 2004; 101: 343–347
   PubMed Web of Science ®Google Scholar
• Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology 2004; 55: 306–319
   PubMed Web of Science ®Google Scholar
• Kreutzberg GW. Microglia: A sensor for pathological events in the CNS. Trends in Neuroscience 1996; 19: 312–318
   PubMed Web of Science ®Google Scholar
• Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer's disease: Interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer's Disease & Associated Disorders 1998; 12: 215–227
   PubMed Web of Science ®Google Scholar
• Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: Peripheral inflammation or signals from the brain?. Journal of Neuroimmunology 2000; 103: 97–102
   PubMed Web of Science ®Google Scholar
• Liu B, Jiang JW, Wilson BC, Du L, Yang SN, Wang JY, et al. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. Journal of Pharmacology & Experimental Therapeutics 2000; 295: 125–132
   PubMed Web of Science ®Google Scholar
• Liu Y, Qin L, Wilson BC, An L, Hong JS, Liu B. Inhibition by naloxone stereoisomers of Aβ1–42-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. Journal of Pharmacology & Experimental Therapeutics 2002; 302: 1212–1219
   PubMed Web of Science ®Google Scholar
• Lombardi VR, Garcia M, Rey L, Cacabelos R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals. Journal of Neuroimmunology 1999; 97: 163–171
   PubMed Web of Science ®Google Scholar
• Lue LF, Walker DG, Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiology & Aging 2001; 22: 945–956
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Steinberg M, Tschantz J, Norton M, Steffens D, Breitner JCS. Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. American Journal of Psychiatry 2000; 157: 708–714
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. Journal of the American Medical Association 2002; 288: 1475–1483
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Reichman WE, Kershaw P, Zhu Y. Long-term outcomes of galantamine treatment in patients with Alzheimer's disease. American Journal of Geriatric Psychiatry 2004; 12: 473–482
   PubMed Web of Science ®Google Scholar
• Malberg JE. Implications of adult hippocampal neurogenesis in antidepressant action. Journal of Psychiatry & Neuroscience 2004; 29: 196–205
   PubMed Web of Science ®Google Scholar
• Martin BK, Meinert CL, Breitner JC, ADAPT Research Group. Double placebo design in a prevention trial for Alzheimer's disease. Controlled Clinical Trials 2002; 23: 93–99
   PubMedGoogle Scholar
• McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996; 47: 425–432
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. Polymorphisms in inflammatory genes and the risk of Alzheimer's disease. Archives in Neurology 2001; 58: 1790–1792
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. Local neuro-inflammation and the progression of Alzheimer's disease. Journal of Neurovirology 2002; 8: 529–538
   PubMed Web of Science ®Google Scholar
• Mehlhorn G, Hollborn M, Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. International Journal of Developmental Neuroscience 2000; 18: 423–431
   PubMed Web of Science ®Google Scholar
• Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003; 302: 1760–1765
   PubMed Web of Science ®Google Scholar
• Mrak RE, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiology & Aging 2005; 26: 349–354
   PubMed Web of Science ®Google Scholar
• Muraro PA, Leist T, Bielekova B, McFarland HF. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. Journal of Neuroimmunology 2000; 111: 186–194
   PubMed Web of Science ®Google Scholar
• Neuroinflammation Working Group. Inflammation and Alzheimer's disease. Neurobiology & Aging 2000; 21: 383–421
   PubMed Web of Science ®Google Scholar
• Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Annals of Neurology 2000; 47: 365–368
   PubMed Web of Science ®Google Scholar
• Paganelli R, Di Iorio A, Patricelli L, Ripani F, Sparvieri E, Faricelli R, et al. Pro-inflammatory cytokines in sera of elderly patients with dementia: Levels in vascular injury are higher than those of mild-moderate Alzheimer's disease patients. Experimental Gerontology 2002; 37: 257–263
   PubMed Web of Science ®Google Scholar
• Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Archives in Neurology 2001; 58: 1985–1992
   PubMed Web of Science ®Google Scholar
• Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 2003; 226: 315–336
   PubMed Web of Science ®Google Scholar
• Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. Journal of Cerebral Blood Flow and Metabolism June 8, 2005, (Epub ahead of 1–20)
   PubMed Web of Science ®Google Scholar
• Rabins PV, Lyketsos CG, Steele CD. Practical Dementia Care. Oxford University Press, New York 1999
   Google Scholar
• Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: A long-term extension trial. Archives in Neurology 2004; 61: 252–256
   PubMed Web of Science ®Google Scholar
• Reale M, Iarlori C, Gambi F, Feliciani C, Salone A, Toma L, et al. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. Journal of Neuroimmunology 2004; 148: 162–171
   PubMed Web of Science ®Google Scholar
• Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62: 66–71, Rofecoxib Protocol 091 Study Group
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine 2003; 348: 1333–1341
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Altenhofen B, Riegel A, Kallmann B, Felgenhauer K. Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis. Multiple Sclerosis 1998; 4: 178–182
   PubMed Web of Science ®Google Scholar
• Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609–1611
   PubMed Web of Science ®Google Scholar
• Rogers J, Lue LF. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochemistry International 2001; 39: 333–340
   PubMed Web of Science ®Google Scholar
• Rombouts SA, Barkhof F, Witter MP, Scheltens P. Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. Neuroscience Letters 2000; 19: 285, 231–233
   Google Scholar
• Rosler N, Wichart I, Jellinger KA. Intra vita lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukin-6 in Alzheimer's disease patients. Acta neurologica Scandinavica 2001; 103: 126–130
   PubMed Web of Science ®Google Scholar
• Sala G, Galimberti G, Canevari C, Raggi ME, Isella V, Facheris M, et al. Peripheral cytokine release in Alzheimer patients: Correlation with disease severity. Neurobiology & Aging 2003; 24: 909–914
   PubMed Web of Science ®Google Scholar
• Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease. Current status and new perspectives. Lancet Neurology 2003; 2: 539–547
   PubMed Web of Science ®Google Scholar
• Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: A 25-year follow-up of the Honolulu-Asia Aging Study. Annals of Neurology 2002; 52: 168–174
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Deciphering the genesis and fate of amyloid ß-protein yields novel therapies for Alzheimer's disease. Journal of Clinical Investigations 2002; 110: 1375–1381
   PubMed Web of Science ®Google Scholar
• Sheng JG, Mrak RE, Griffin WS. Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms. Acta neuropathologica (Berl) 1997; 94: 1–5
   PubMed Web of Science ®Google Scholar
• Shors TJ, Miesegaes G, Beylin A, Zhao M, Rydel T, Gould E. Neurogenesis in the adult is involved in the formation of trace memories. Nature 2001; 410: 372–376
   PubMed Web of Science ®Google Scholar
• Song DK, Im YB, Jung JS, Cho J, Suh HW, Kim YH. Central beta-amyloid peptide-induced peripheral interleukin-6 responses in mice. Journal of Neurochemistry 2001; 76: 1326–1335
   PubMed Web of Science ®Google Scholar
• Souetre E, Thwaites RM, Yeardley HL. Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease. British Journal of Psychiatry 1999; 174: 51–55
   PubMed Web of Science ®Google Scholar
• Tancredi V, D'Arcangelo G, Grassi F, Tarroni P, Palmieri G, Santoni A, Eusebi F. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neuroscience Letter 1992; 146: 176–178
   PubMed Web of Science ®Google Scholar
• Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001; 32: 181–184
   PubMed Web of Science ®Google Scholar
• Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer's disease and vascular dementia. Journal of Clinical Immunology 1999; 19: 223–230
   PubMed Web of Science ®Google Scholar
• Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. Journal of Neurology, Neurosurgery & Psychiatry 2003; 74: 1200–1205
   PubMed Web of Science ®Google Scholar
• Tehranian R, Hasanvan H, Iverfeldt K, Post C, Schultzberg M. Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576. Neuroscience Letter 2001; 301: 54–58
   PubMed Web of Science ®Google Scholar
• Terry AV, Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development. Journal of Pharmacology & Experimental Therapeutics 2003; 306: 821–827
   PubMed Web of Science ®Google Scholar
• Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; 30: 1204–1215
   PubMed Web of Science ®Google Scholar
• Vallieres L, Campbell IL, Gage FH, Sawchenko PE, et al. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. Journal of Neuroscience 2002; 22: 486–492
   PubMed Web of Science ®Google Scholar
• Versijpt JJ, Dumont F, Van Laere KJ, Decoo D, Santens P, Audenaert K, et al. Assessment of neuro-inflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. European Journal of Neurology 2003; 50: 39–47
   Web of Science ®Google Scholar
• Versijpt J, Debruyne JC, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: A correlative study. Multiple Sclerosis 2005; 11: 127–134
   PubMed Web of Science ®Google Scholar
• von Bernhardi R, Eugenin J. Microglial reactivity to beta-amyloid is modulated by astrocytes and pro-inflammatory factors. Brain Research 2004; 1025: 186–193
   PubMed Web of Science ®Google Scholar
• Walker LC, Ibegbu CC, Todd CW, Robinson HL, Jucker M, LeVine H, III, et al. Emerging prospects for the disease-modifying treatment of Alzheimer's disease. Biochemical Pharmacology 2005; 69: 1001–1008
   PubMed Web of Science ®Google Scholar
• Watterson DM, Velentza AV, Zasadzki M, Craft JM, Haiech J, Van Eldik LJ. Discovery of a new class of synthetic protein kinase inhibitors that suppress selective aspects of glial activation and protect against beta-amyloid induced injury: A foundation for future medicinal chemistry efforts focused on targeting Alzheimer's disease progression. Journal of Molecular Neuroscience 2003; 20: 411–423
   PubMed Web of Science ®Google Scholar
• Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002; 59: 371–378
   PubMed Web of Science ®Google Scholar
• Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. Donepezil for the symptomatic treatment of patients with mild-to-moderate Alzheimer's disease: A meta-analysis of individual patient data from randomized controlled trials. International Journal of Geriatric Psychiatry 2004; 19: 624–633
   PubMed Web of Science ®Google Scholar
• Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. Journal of Neuroscience 2003; 23: 3745–3751
   PubMed Web of Science ®Google Scholar
• Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. Journal of Neuroscience 2004a; 24: 6144–6151
   PubMed Web of Science ®Google Scholar
• Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiological Disorders 2004b; 15: 11–20
   PubMed Web of Science ®Google Scholar
• Winblad B, Jelic V. Long-term treatment of Alzheimer's disease: Efficacy and safety of acetylcholinesterase inhibitors. Alzheimer's Disease & Associated Disorders 2004; 18: S2–S8
   PubMed Web of Science ®Google Scholar
• Wolfe MS. Therapeutic strategies for Alzheimer's disease. Nature Reviews. Drug Discovery 2002; 1: 859–866
   PubMed Web of Science ®Google Scholar
• Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003; 61: 76–80
   PubMed Web of Science ®Google Scholar